Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E25.06 EPS (ttm)6.70 Insider Own0.10% Shs Outstand757.91M Perf Week2.65%
Market Cap127.26B Forward P/E16.03 EPS next Y10.47 Insider Trans-7.46% Shs Float755.85M Perf Month4.54%
Income5.16B PEG2.26 EPS next Q2.10 Inst Own82.60% Short Float1.37% Perf Quarter5.62%
Sales20.06B P/S6.34 EPS this Y0.90% Inst Trans-0.09% Short Ratio2.98 Perf Half Y17.96%
Book/sh33.83 P/B4.96 EPS next Y12.47% ROA7.50% Target Price176.79 Perf Year50.54%
Cash/sh35.66 P/C4.71 EPS next 5Y11.10% ROE21.00% 52W Range106.12 - 173.60 Perf YTD5.97%
Dividend3.16 P/FCF22.32 EPS past 5Y8.20% ROI10.20% 52W High-3.28% Beta0.57
Dividend %1.88% Quick Ratio4.60 Sales past 5Y6.50% Gross Margin80.00% 52W Low58.22% ATR3.68
Employees17900 Current Ratio5.00 Sales Q/Q6.40% Oper. Margin34.70% RSI (14)59.41 Volatility2.11% 2.12%
OptionableYes Debt/Eq1.19 EPS Q/Q25.60% Profit Margin25.70% Rel Volume0.73 Prev Close169.17
ShortableYes LT Debt/Eq1.17 EarningsApr 21 AMC Payout35.90% Avg Volume3.47M Price167.91
Recom2.40 SMA203.27% SMA504.78% SMA20012.83% Volume2,548,250 Change-0.74%
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Apr-23-14Reiterated Oppenheimer Perform $121 → $122
Mar-21-14Reiterated Barclays Equal Weight $115 → $130
Jan-31-14Reiterated Argus Buy $130 → $135
Nov-20-13Reiterated Deutsche Bank Buy $138 → $142
Aug-29-13Reiterated UBS Buy $121 → $124
Aug-27-13Reiterated Barclays Overweight $105 → $115
Jul-31-13Reiterated Oppenheimer Perform $100 → $109
Apr-24-13Reiterated Deutsche Bank Buy $108 → $115
Apr-15-13Reiterated Barclays Equal Weight $90 → $105
Apr-08-13Reiterated RBC Capital Mkts Outperform $95 → $105
Jan-25-13Upgrade Argus Hold → Buy $96
Jan-24-13Reiterated UBS Buy $96 → $98
Apr-25-15 09:10AM  Massive Energy Trade Highlights High-Profile Insider Selling This Week at 24/7 Wall St.
Apr-24-15 08:08PM  Final Glance: Biotechnology companies
04:31PM  Stock Market Video Analysis for Week Ending 4/24/15
03:16PM  Eli Lilly (LLY) Earnings Analysis: By the Numbers
01:36PM  Midday Glance: Biotechnology companies
10:55AM  Early Glance: Biotechnology companies
09:58AM  Seattle Genetics' exec: Here's how to stay an independent biotech in Seattle at bizjournals.com
Apr-23-15 05:00PM  Kemper Freeman still unsure Expedia is moving to Seattle at bizjournals.com
02:14PM  AbbVie Profit Rises on Broad Sales Growth at The Wall Street Journal
10:48AM  AbbVie raises outlook as Humira again delivers earnings beat
10:30AM  3 Top Stocks to Buy That Delivered Great Earnings at 24/7 Wall St.
09:47AM  AbbVie raises guidance after 1Q sales beat
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Medicines, Athersys and Alnylam - Press Releases
08:50AM  Top Analyst Upgrades and Downgrades: Barrick, Facebook, Halcon, Qualcomm, Synchrony, Texas Instruments and More at 24/7 Wall St.
03:57AM  Novartis starts to reap rewards of revamp at Financial Times
Apr-22-15 01:21PM  Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampio & Athersys - Analyst Blog
11:53AM  Stocks Mildly Higher; China Nods To Visa, MasterCard at Investor's Business Daily
11:43AM  Technological Innovation Increases Amgens Earnings and Stock Price
11:43AM  Amgen: But What About the Biosimilars? at Barrons.com
10:18AM  Amgen Earnings Reveals Ugly Truth About Drug Pricing and Sales 'Growth' at TheStreet
09:15AM  Amgen Beats on Q1 Earnings & Revenues, Ups Earnings View - Analyst Blog
08:29AM  Amgen (AMGN) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
07:58AM  Early movers: BA, KO, TMO, NLSN, AN & more at CNBC
06:30AM  Amgen tops estimates, grows profit 51% AAP
04:43AM  Roche boosted by US drugs sales at Financial Times
Apr-21-15 07:27PM  Amgen tops estimates with 51 percent spike in 1Q profit
06:28PM  Amgen earnings boosted by higher drug prices, lower R&D
06:00PM  Amgen, Illumina Earnings Hot, Intuitive Surgical Not at Investor's Business Daily
05:18PM  Amgen raises full-year guidance
05:13PM  After-hours buzz: Amgen, Yahoo, Chipotle & more at CNBC
05:04PM  Amgen tops Street 1Q forecasts
05:00PM  Amgen Profit Beats Estimates as Drugmaker Raises Forecast at Bloomberg
05:00PM  Amgen Inc Earnings Call scheduled for 5:00 pm ET today
04:52PM  Amgen earnings top analyst forecasts at Los Angeles Times
04:38PM  Amgen Jump in After Hours on Higher Earnings, Guidance at Barrons.com
04:37PM  Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 at noodls
04:29PM  Amgen Earnings Point to More Froth in the Biotech Sector at 24/7 Wall St.
04:28PM  Amgen (AMGN) Stock Gains in After-Hours Trading Today on Earnings Beat and Raised Guidance at TheStreet
04:24PM  Amgen 1st-quarter profit boosted by drug price rises, lower R&D
04:19PM  Earnings Parade: Chipotle & Yum
04:16PM  AMGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:09PM  Amgen handily beats Street on strong drug sales at CNBC
04:05PM  Amgen beats on top & bottom line
04:01PM  Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 PR Newswire
03:13PM  Strategist: Amgen To Move 3% On Q1 Earnings News
02:29PM  Adam Sarhan: Amgen Shares To Go Higher Following Q1 Results
02:04PM  What The Street...And The Crowd Are Watching At Amgen Before Earnings
11:35AM  Will Amgen Earnings Shape Biotech for the Rest of 2015? at 24/7 Wall St.
10:32AM  Stocks mixed amid earnings; Nasdaq leads gains at CNBC
08:08AM  Wall Street optimistic on bumper earnings day at CNBC
07:07AM  Q1 2015 Amgen Inc Earnings Release - After Market Close
Apr-20-15 03:20PM  Oncolytics' Reolysin Gets One More Orphan Drug Status - Analyst Blog
03:08PM  TrovaGene's (TROV) PCM Data Impresses, Shares Rally - Analyst Blog
02:58PM  Will Amgen (AMGN) Keep Earnings Streak Alive in 1Q? - Analyst Blog
02:05PM  Business events scheduled for Tuesday
01:29PM  Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - Analyst Blog
12:03PM  Amgen sees upside earnings play
Apr-17-15 05:10PM  Here's what analysts are eyeing next week
04:53PM  Biotech Investors Shouldn't Miss These Stocks This Earnings - Earnings ESP
04:00PM  P-I globe building gets a new tenant IMS Health/Appature as companies flock to the waterfront at bizjournals.com
02:49PM  Why This Trader Is Watching Amgen
Apr-16-15 04:46PM  Amgen Announces Webcast Of 2015 First Quarter Financial Results at noodls
04:35PM  FDA approves Amgens heart failure drug Corlanor at bizjournals.com
04:31PM  Amgen Earnings Preview: 5 Questions to Ask at Investopedia
04:05PM  Amgen Announces Webcast Of 2015 First Quarter Financial Results PR Newswire
04:04PM  Amgen Has A Big Launch Coming Up
02:30PM  2 Pairs Trades To Avoid A Market Correction
02:26PM  FDA approves first generic version of Teva MS drug Copaxone Reuters
01:35PM  United Therapeutics Corporation (UTHR), Amgen, Inc. (AMGN): Neil Shahs Top Healthcare Picks Dominated S&P 500 Index in January-March at Insider Monkey
11:30AM  Amgen Gets FDA Nod for Chronic Heart Failure Drug Corlanor - Analyst Blog
10:05AM  5 Must-See Stock Charts to Trade for Gains at TheStreet
09:26AM  What Were Trading
08:44AM  FDA approves Amgens heart-failure drug Corlanor at MarketWatch
Apr-15-15 07:20PM  FDA approves Amgen heart failure drug Corlanor at Los Angeles Times
06:10PM  FDA Approves Amgen's Heart-Failure Drug Corlanor at The Wall Street Journal
06:10PM  Biogen Reports New Data from Acute Optic Neuritis Study - Analyst Blog
06:10PM  FDA approves new type of heart failure drug from Amgen
06:05PM  FDA Approves Amgen Heart Failure Drug at Forbes
05:56PM  FDA Approves Corlanor® (ivabradine) To Reduce The Risk Of Hospitalization For Worsening Heart Failure In Patients With Chronic Heart Failure at noodls
05:08PM  After-hours buzz: Netflix, General Motors & more at CNBC
05:04PM  FDA Approves Corlanor® (ivabradine) To Reduce The Risk Of Hospitalization For Worsening Heart Failure In Patients With Chronic Heart Failure PR Newswire
04:46PM  U.S. FDA approves Amgen heart failure drug Reuters
02:41PM  Ariad Pharmaceuticals, Inc. (ARIA), Amgen, Inc. (AMGN): How Sarissa Capitals Top Picks Beat the Market at Insider Monkey
Apr-14-15 04:45PM  Alnylam Reports Publication of New Data on Hemophilia Drug - Analyst Blog
04:02PM  AVEO Upgraded to Strong Buy, Add to Your Portfolio - Analyst Blog
04:00PM  ARCA biopharma Gains on Fast Track Status for Gencaro - Analyst Blog
02:45PM  Immunotherapy could cure cancer, and Seattle companies have raised millions to make it happen at bizjournals.com
10:45AM  J&J Beats on Q1 Earnings, Cuts View on Currency Woes - Analyst Blog
Apr-13-15 03:27PM  Amgen Upgraded to Strong Buy, Perfect for Your Portfolio - Analyst Blog
11:19AM  AbbVie Upgraded On $7.8 Billion Imbruvica Potential at Investor's Business Daily
10:10AM  Stock Market News for April 13, 2015 - Market News
08:35AM  Short Sellers Increase Their Bets Against Biotech Stocks at 24/7 Wall St.
Apr-10-15 10:10AM  Stock Market News for April 10, 2015 - Market News
Apr-09-15 07:36PM  5 biotech bets: Trading a surging sector at CNBC
05:00PM  5 biotech bets: Large & small
04:20PM  Halozyme to Advance PEGPH20 Following FDA Meet - Analyst Blog
03:53PM  Amgen's Most Surprising Success Is Its Dividend at Investopedia
Apr-08-15 02:53PM  Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blog
01:20PM  Biosimilar drugs: spot the difference at Financial Times
12:58PM  Top trades for the 2nd half
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with AstraZeneca Plc; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tross Stuart ASVP, Human ResourcesApr 23Sale169.313,012509,96421,923Apr 24 04:53 PM
Harper Sean EEVP, Research & DevelopmentApr 22Sale171.5828,0004,804,24047,920Apr 23 05:04 PM
Tross Stuart ASVP, Human ResourcesMar 03Sale157.744,415696,42720,237Mar 04 08:25 PM
BALTIMORE DAVIDDirectorMar 02Sale158.763,647579,01131,159Mar 03 08:55 PM
BALTIMORE DAVIDDirectorFeb 19Option Exercise42.135,000210,65036,159Feb 23 04:13 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Option Exercise42.1384,0003,538,920258,641Feb 12 09:09 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Sale152.6922,0003,359,116218,102Feb 12 09:09 PM
COFFMAN VANCE DDirectorFeb 06Option Exercise42.135,000210,65038,460Feb 06 06:23 PM
HERRINGER FRANK CDirectorFeb 05Option Exercise42.135,000210,65025,449Feb 05 08:11 PM
HERRINGER FRANK CDirectorFeb 05Buy152.293,000456,8702,000Feb 05 08:11 PM
de Carbonnel FrancoisDirectorDec 03Sale168.013,000504,04119,159Dec 03 05:00 PM
COFFMAN VANCE DDirectorSep 05Option Exercise56.7920,0001,135,80041,623Sep 09 06:54 PM
Harper Sean EEVP, Research & DevelopmentAug 05Sale127.2914,0001,782,12659,503Aug 07 04:22 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Option Exercise56.644,130233,91122,719May 22 05:15 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Sale112.834,130465,98418,589May 22 05:15 PM
Bradway Robert AChairman, CEO and PresidentMay 12Buy111.7789499,919185,013May 12 08:33 PM
Michael A KellyActing CFOApr 28Sale110.452,065228,07241,041Apr 29 05:48 PM